Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Rectal Neoplasms × Hydralazine × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Uterine Cervical Neoplasms 3 Refractory Solid Tumors 1 Rectal Neoplasms 1 Ovarian Neoplasms 1 Lung Neoplasms 1 Locally Advanced Breast Cancer 1 Breast Neoplasms 1

Interventions

Oxaliplatin 238 Fluorouracil 231 Capecitabine 193 Leucovorin 183 Irinotecan 132 Radiotherapy 120 Bevacizumab 97 Cetuximab 68 Surgical Procedures, Operative 48 Folfox protocol 45 Neoadjuvant Therapy 41 Drug Therapy 37 Radiation 35 Chemotherapy, Adjuvant 33 Chemoradiotherapy 33 Panitumumab 24 XELOX 22 Radiotherapy, Intensity-Modulated 21 Magnetic Resonance Spectroscopy 17 Proctectomy 16 Floxuridine 16 Surveys and Questionnaires 14 Immunohistochemistry 14 pembrolizumab 13 Laparoscopy 13 IFL protocol 13 Early Intervention, Educational 13 Biopsy 13 trifluridine tipiracil drug combination 12 Nivolumab 12

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT00575640 2015-03-04

Hydralazine as a Demethylating Agent in Rectal Cancer

University of Arkansas

Phase 1/2 Withdrawn

Gastrointestinal

Rectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡